Literature DB >> 17115063

Significance of additional high-dose cytarabine in combination with cyclophosphamide plus total body irradiation regimen for allogeneic stem cell transplantation.

Y Inamoto1, T Nishida, R Suzuki, K Miyamura, H Sao, H Iida, T Naoe, F Maruyama, N Hirabayashi, M Hamaguchi, T Iseki, M Kami, K Yano, H Takeyama, Y Morishita, Y Morishima, Y Kodera.   

Abstract

The combination of cyclophosphamide (CY) and total body irradiation (TBI) has been used as a standard conditioning regimen for allogeneic transplantation. Several studies showed an advantage of adding high-dose cytarabine (HDCA) to this regimen. To clarify the significance of additional HDCA, we conducted a retrospective multicenter study and compared the clinical results of these two regimens. From June 1985 to March 2003, 219 patients with hematological malignancies underwent allogeneic transplantation after conditioning with CY+TBI 12Gy (n=73) or CA+CY+TBI 12Gy (n=146). Engraftment, overall survival, transplant-related mortality (TRM), relapse rate and incidence of graft-versus-host disease (GVHD) were compared according to risks and donors. Addition of HDCA had no impact on the relapse rate in all subgroups, and it was associated with lower TRM among standard-risk patients after related transplantation, and with higher TRM and worse survival among standard-risk patients after unrelated transplantation. The incidence of acute GVHD was not significantly different between the two regimens, and HDCA resulted in a higher incidence of chronic GVHD among standard-risk patients after related transplantation. In summary, addition of HDCA is not beneficial for high-risk patients, and is not recommended for standard-risk patients receiving unrelated transplantation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17115063     DOI: 10.1038/sj.bmt.1705543

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

1.  Clinical significance of the administration of cytarabine or thiotepa in addition to total body irradiation and cyclophosphamide for allogeneic hematopoietic cell transplantation in patients with acute leukemia.

Authors:  Takayoshi Tachibana; Masatsugu Tanaka; Maki Hagihara; Rika Kawasaki; Etsuko Yamazaki; Hideyuki Koharazawa; Jun Taguchi; Naoto Tomita; Katsumichi Fujimaki; Rika Sakai; Hiroyuki Fujita; Shin Fujisawa; Atsuo Maruta; Yoshiaki Ishigatsubo; Heiwa Kanamori
Journal:  Int J Hematol       Date:  2015-07-15       Impact factor: 2.490

2.  Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy.

Authors:  Yasuyuki Arai; June Takeda; Kazunari Aoki; Tadakazu Kondo; Satoshi Takahashi; Yasushi Onishi; Yukiyasu Ozawa; Nobuyuki Aotsuka; Yasuji Kouzai; Hirohisa Nakamae; Shuichi Ota; Chiaki Nakaseko; Hiroki Yamaguchi; Koji Kato; Yoshiko Atsuta; Akiyoshi Takami
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

3.  Clinical separation of cGvHD and GvL and better GvHD-free/relapse-free survival (GRFS) after unrelated cord blood transplantation for AML.

Authors:  C-C Zheng; X-Y Zhu; B-L Tang; X-H Zhang; L Zhang; L-Q Geng; H-L Liu; Z-M Sun
Journal:  Bone Marrow Transplant       Date:  2016-07-04       Impact factor: 5.483

4.  The Efficacy of an Oral Elemental Diet in Patients Undergoing Hematopoietic Stem Cell Transplantation.

Authors:  Takanobu Morishita; Natsuko Tsushita; Kanae Imai; Toshiyasu Sakai; Kotaro Miyao; Reona Sakemura; Tomonori Kato; Keiko Niimi; Yoshitaka Ono; Masashi Sawa
Journal:  Intern Med       Date:  2016-12-15       Impact factor: 1.271

5.  The Confirmation of Safety for the Intensified Conditioning Regimens: A Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation for Non-Remission Hematological Malignant Diseases.

Authors:  Shuro Yoshida; Hideho Henzan; Toshiyuki Ueno; Takuya Shimakawa; Yayoi Matsuo; Takuro Kuriyama; Noriyuki Saito; Ichiro Kawano; Akihiko Numata; Ken Takase; Tadafumi Iino; Tetsuya Eto
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2018-04-01

6.  Clinical significance of high-dose cytarabine added to cyclophosphamide/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy.

Authors:  Yasuyuki Arai; Kazunari Aoki; June Takeda; Tadakazu Kondo; Tetsuya Eto; Shuichi Ota; Hisako Hashimoto; Takahiro Fukuda; Yukiyasu Ozawa; Yoshinobu Kanda; Chiaki Kato; Mineo Kurokawa; Koji Iwato; Makoto Onizuka; Tatsuo Ichinohe; Yoshiko Atsuta; Akiyoshi Takami
Journal:  J Hematol Oncol       Date:  2015-09-04       Impact factor: 17.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.